Back To Active Research

Setmelanotide Obesity Study

Rhythm Pharmaceuticals is currently recruiting for a Phase 2 clinical study of an investigational therapy to help reduce weight and hunger in individuals diagnosed with Smith-Magenis Syndrome and rare genetic diseases of obesity.

The study is enrolling individuals:

  • Age 6 years or older
  • With a confirmed diagnosis of Smith-Magenis Syndrome
  • With weight defined as
    • BMI of ≥ 30 kg/m for individuals ≥ 16 years of age
    • BMI of ≥ 95th percentile for individuals 6-16 years of age

Study participation includes:

  • 6 visits to the study center over a period of ~28 weeks
  • Daily study therapy administration during the treatment period (~16 weeks)
  • Completion of daily questionnaires
  • Medical examinations and safety monitoring (~once a month)
  • Blood tests

If you are interesting in learning more, please email and please indicate the city, state, or country in which you reside. Identifier: NCT03013543